Brokerages expect Uniqure NV (NASDAQ:QURE) to report $2.91 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Uniqure’s earnings, with the lowest sales estimate coming in at $2.00 million and the highest estimate coming in at $3.50 million. Uniqure posted sales of $2.58 million in the same quarter last year, which would suggest a positive year over year growth rate of 12.8%. The company is scheduled to report its next quarterly earnings results on Wednesday, March 13th.
On average, analysts expect that Uniqure will report full year sales of $12.99 million for the current year, with estimates ranging from $11.70 million to $14.55 million. For the next year, analysts expect that the company will post sales of $11.57 million, with estimates ranging from $8.00 million to $14.40 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for Uniqure.
QURE has been the topic of a number of recent analyst reports. Zacks Investment Research lowered Uniqure from a “hold” rating to a “sell” rating in a research note on Friday, January 11th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $68.00 price objective on shares of Uniqure in a research note on Friday, February 8th. BidaskClub lowered shares of Uniqure from a “sell” rating to a “strong sell” rating in a research report on Tuesday, November 13th. Guggenheim assumed coverage on shares of Uniqure in a research report on Monday, December 17th. They set a “buy” rating and a $35.00 price objective for the company. Finally, HC Wainwright set a $48.00 target price on shares of Uniqure and gave the stock a “buy” rating in a research note on Wednesday, November 7th. Two research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $55.20.
In other news, CEO Matthew C. Kapusta sold 19,085 shares of the stock in a transaction dated Monday, January 28th. The shares were sold at an average price of $31.42, for a total value of $599,650.70. Following the completion of the sale, the chief executive officer now owns 490,028 shares in the company, valued at $15,396,679.76. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Alexander Edward Kuta III sold 1,052 shares of the stock in a transaction dated Monday, January 28th. The shares were sold at an average price of $31.29, for a total transaction of $32,917.08. Following the transaction, the senior vice president now owns 26,578 shares of the company’s stock, valued at approximately $831,625.62. The disclosure for this sale can be found here. In the last ninety days, insiders sold 43,014 shares of company stock valued at $1,320,169. 1.56% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Advisor Group Inc. raised its holdings in Uniqure by 5.3% during the 4th quarter. Advisor Group Inc. now owns 9,966 shares of the biotechnology company’s stock valued at $288,000 after buying an additional 502 shares during the period. Northern Trust Corp boosted its position in shares of Uniqure by 2.5% in the 4th quarter. Northern Trust Corp now owns 33,086 shares of the biotechnology company’s stock valued at $954,000 after purchasing an additional 797 shares during the period. Exane Derivatives acquired a new stake in Uniqure during the 4th quarter worth approximately $41,000. Bank of New York Mellon Corp increased its stake in Uniqure by 12.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 18,747 shares of the biotechnology company’s stock valued at $682,000 after purchasing an additional 2,129 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its holdings in shares of Uniqure by 24.2% during the third quarter. Wells Fargo & Company MN now owns 17,829 shares of the biotechnology company’s stock worth $649,000 after purchasing an additional 3,472 shares during the last quarter. 60.49% of the stock is owned by hedge funds and other institutional investors.
NASDAQ:QURE opened at $36.98 on Thursday. Uniqure has a 12-month low of $20.29 and a 12-month high of $43.23. The company has a quick ratio of 7.56, a current ratio of 7.56 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $1.39 billion, a P/E ratio of -12.58 and a beta of 0.87.
Uniqure Company Profile
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.
Further Reading: What is dollar cost averaging (DCA)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.